Patents Issued in January 7, 2020
  • Patent number: 10526372
    Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: January 7, 2020
    Assignee: ALBA THERAPEUTICS CORPORATION
    Inventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
  • Patent number: 10526373
    Abstract: The present invention provides a peptide which shows a melanin generation-promoting activity. The peptide of the present invention increases the activity and expression of tyrosinase and increases the expression of factors related to melanin generation, thereby showing an excellent effect in melanin generation. The peptide of the present invention can be used for preventing, alleviating, and treating hypomelanosis. The above-mentioned superior activity and stability of the peptide of the present invention allows the peptide to be very favorably applied to medicines, quasi drugs, and cosmetics.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: January 7, 2020
    Assignee: Caregen Co., Ltd.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung-Ji Lee, Jan Di Kim
  • Patent number: 10526374
    Abstract: Disclosed are a protein and a gene each of which is a factor involved in latent infection with a herpesvirus. An antibody against the factor was detected in approximately 50% of patients suffering from mental disorders, whereas the antibody was hardly detected in healthy persons. Further, a mouse having SITH-1 introduced therein developed a mental disorder such as a manic-depressive illness or depression-like disorder. Based on these findings, it is possible to provide a method for objectively determining a mental disorder and an animal model of a mental disorder.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: January 7, 2020
    Assignees: VIRUS IKAGAKU KENKYUSHO INC., JAPAN TOBACCO INC.
    Inventors: Kazuhiro Kondo, Nobuyuki Kobayashi
  • Patent number: 10526375
    Abstract: The present invention provides, among other things, systems (e.g., comprising compositions and/or methods) for diagnosis, prophylaxis, treatment, prevention, and/or characterization of influenza transmission and/or infection. The present invention also provides methods for monitoring influenza variants for their potential to present a pandemic risk to humans.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: January 7, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Kannan Tharakaraman, Rahul Raman, Akila Jayaraman, Nathan Wilson Stebbins, Ram Sasisekharan
  • Patent number: 10526376
    Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: January 7, 2020
    Assignee: University of Copenhagen
    Inventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
  • Patent number: 10526377
    Abstract: The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of an proteins. The compositions may also be used to detect amyloid.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: January 7, 2020
    Assignee: PROCLARA BIOSCIENCES, INC.
    Inventors: Rajaraman Krishnan, Richard Fisher
  • Patent number: 10526378
    Abstract: The invention provides a method for encapsulating a protein of interest, the method comprising the step of expressing a fusion protein comprising an N-terminal region of a rearrangement hot spot (RHS)-repeat-containing protein fused to the protein of interest. The invention further provides applications for the encapsulation, release and delivery of the protein of interest. The invention also encompasses the encapsulated protein of interest and compositions comprising the encapsulated protein of interest. The invention also provides uses of the encapsulated protein of interest, optionally after release from encapsulation, to control pests. The encapsulated protein of interest may for example be produced via expression in a plant to control a pest of the plant, such as an insect pest.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: January 7, 2020
    Assignee: AgResearch Limited
    Inventors: Jason Nicholas Busby, Jeremy Shaun Lott, Mark Robin Holmes Hurst
  • Patent number: 10526379
    Abstract: A method of producing a fusion protein is provided. The method includes: a) contacting a first protein with a second protein under conditions that enable the formation of an isopeptide bond between said proteins to form a linked protein; and b) contacting the linked protein from (a) with a third protein under conditions that enable the formation of an isopeptide bond between said third protein and said linked protein to form a fusion protein. Peptide linkers and the use of orthogonal pairs of said linkers in the synthesis of fusion proteins are also provided. Recombinant proteins comprising said linkers, nucleic acid molecules encoding said proteins and linkers, vectors comprising said nucleic acid molecules and host cells comprising said vectors and nucleic acid molecules are also contemplated.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: January 7, 2020
    Assignee: Oxford University Innovation Limited
    Inventor: Mark Howarth
  • Patent number: 10526380
    Abstract: A nucleic acid molecule encoding a fusion protein composed of a plant cryptochrome at the amino terminus, and a GTPase-Activating Protein SH3 Domain-Binding Protein (G3BP) is provided for light-dependent, G3BP-mediated stress granule formation.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: January 7, 2020
    Assignee: St. Jude Children's Research Hospital
    Inventors: Joseph Paul Taylor, Peipei Zhang
  • Patent number: 10526381
    Abstract: Compositions containing multivalent and monovalent multispecific complexes having scaffolds such as antibodies that support such binding functionalities are described. The use of and methods of compositions containing multivalent and monovalent multispecific complexes having scaffolds, such as antibodies, that support such binding functionalities are also described.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: January 7, 2020
    Assignee: Zygenia, Inc.
    Inventors: Viktor Roschke, David Lafleur, David M. Hilbert, Peter Kiener
  • Patent number: 10526382
    Abstract: The present disclosure provides hNGAL muteins that bind Ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: January 7, 2020
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Rachida SIham Bel Aiba, Andrea Allersdorfer, Alexander Wiedenmann, Christine Rothe, Shane Olwill, Hendrik Gille, Laurent Audoly
  • Patent number: 10526383
    Abstract: The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereat: or a ghrelin splice variant-like compound for the preparation of a medicament for one or more of: treatment and/or prevention of neuronal damage and/or neurodegeneration and, prophylaxis or treatment of neuronal damage and/or neurodegenerative disease, Parkinson's disease, Alzheimer's disease, depression stimulation of neuronal activity. A further aspect relates to a number of new ghrelin splice variant like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin splice variant-like compounds.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: January 7, 2020
    Inventor: Liat Mintz
  • Patent number: 10526384
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: January 7, 2020
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Marlon Hinner, Laurent Audoly, Martin Huelsmeyer, Kristian Jensen, Gabriele Matschiner, Shane Olwill, Alexander Wiedenmann, Andrea Allersdorfer
  • Patent number: 10526385
    Abstract: Provided in the present invention are a YAP protein inhibiting polypeptide and application thereof. In particular, the present invention obtains a key binding site of YAP protein and TEAD, screens a polypeptide with best YAP inhibitory activity and modifies the polypeptide, such as adding a disulfide linkage, replacing an amino acid, removing and/or adding (for example, adding a cell-penetrating element), and finally screens and verifies the obtaining of a series of polypeptides with YAP protein activity inhibiting effect and good stability. Experiments show that the polypeptide of the present invention can effectively inhibit the binding activity between YAP protein and TEAD, thus providing good therapeutic effect on digestive tract tumors (especially liver cancer).
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: January 7, 2020
    Assignee: BAO KANG BIOMEDICAL HEALTHCARE INC
    Inventor: Kangshan Li
  • Patent number: 10526386
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 7, 2020
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
  • Patent number: 10526387
    Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 7, 2020
    Assignees: BIONTECH PROTEIN THERAPEUTICS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVRESITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
    Inventors: Thorsten Klamp, Ugur Sahin, Ozlem Tureci, Michael Koslowski, Thomas Hiller, Jens Schumacher
  • Patent number: 10526388
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: January 7, 2020
    Assignee: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Patent number: 10526389
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: January 7, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Claudia Wagner, Julia Leibold, Colette Song
  • Patent number: 10526390
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: January 7, 2020
    Assignee: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Patent number: 10526391
    Abstract: Molecular constructs and dual recognition constructs having a sequence encoding a TCR affinity weakening motif, and DNA and RNA sequences corresponding thereto, are presented. Modified T-cells and other cells transformed with the molecular contracts express a modified TCR that imparts a reduction, in non-specific binding, -an enhancement of binding specificity and an enhancement of binding affinity for a target antigen, compared to non-transformed (wild-type, native) T-cells, are described. The modified TCRs possess an affinity enhancing motif and an affinity weakening motif. Methods of transforming cells and methods of using enriched populations of transformed cells, in the treatment of cancer and infections arid T-cell mediated pathologies are provided. The affinity weakening motif imparts a weakened interaction, of a TCR with major histocompatibility complex proteins, such as HLA proteins in humans.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: January 7, 2020
    Assignees: The University of Notre Dame du Lac, University of Massachusetts
    Inventors: Brian Baker, Lance Hellman, Brian Pierce, Zhiping Weng
  • Patent number: 10526392
    Abstract: A novel synthetic biology-based ADCC technology is provided that enhances or enables ADCC response. The novel ADCC technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: January 7, 2020
    Assignee: 1GLOBE BIOMEDICAL CO., LTD.
    Inventors: Chiang J. Li, Shyam Unniraman
  • Patent number: 10526393
    Abstract: The present invention relates to a method for promoting virus infection and increasing virus production, by using a cell line having lost Bst2 gene functions and, more specifically, to a method for promoting target virus infection and increasing target virus production, in addition to promoting virus budding and inhibiting host cell apoptosis by removing the Bst2 gene from a cell line having the ability to produce a virus. According to the present invention, the method for promoting target virus infection and increasing target virus production, by using an animal cell line having lost Bst2 gene functions, can improve production yields of a target virus and an antigen protein, and thus can be useful for the preparation of vaccines for treating and preventing viral diseases.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: January 7, 2020
    Assignee: IMMUNOMAX CO., LTD.
    Inventors: Se-Ho Park, Eunbi Yi
  • Patent number: 10526394
    Abstract: The invention relates, firstly, to a biomolecule-releasing cell characterised by a surface protein with an extracellularly exposed ligation peptide sequence for enzymatic conjugation of an adapter ligand, said adapter ligand being suitable for the indirect or direct coupling of a molecular catcher structure which has at least one specific binding site for the released biomolecules and which is at a distance from the specific binding site, secondly, to a method for selecting such a cell, and thirdly, to a means for this method comprising the surface protein that is characterised by an extracellularly exposable ligation peptide sequence for enzymatic conjugation of an adapter ligand, a nucleic acid coding for the surface protein, an expression vector for the nucleic acid, and a cell containing the expression vector.
    Type: Grant
    Filed: April 20, 2014
    Date of Patent: January 7, 2020
    Assignee: NEW / ERA / MABS GMBH
    Inventors: Martin Listek, Katja Hanack, Burkhard Micheel
  • Patent number: 10526395
    Abstract: A method for generating detergent-solubilized G-protein coupled receptors (GPCRs) in powdered form. The powdered GPCRs is storable at temperatures of ?20° C. or lower and for durations of 365 days or longer without substantial loss of functionality of the GPCRs after rehydration as compared to a pre-frozen state. The method can maintain minimal detergent to protein ratio in molar concentrations. The method can further generate GPCRs with specific water or deuterium content as required in certain experiments, such as mass spectrometry, NMR spectroscopy, or quasi-elastic neutron scattering (QENS).
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: January 7, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Michael F. Brown, Suchithranga Perera, Udeep Chawla
  • Patent number: 10526396
    Abstract: The present invention concerns the use of a thioether alkylation process for modulating the lower critical solution temperature of an elastin-like polypeptide comprising at least one methionine residue. It also concerns derivatives of elastin-like polypeptides and their preparation process.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: January 7, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE BORDEAUX, INSTITUT POLYTECHNIQUE DE BORDEAUX, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Sébastien Jean Marie Lecommandoux, Elisabeth Béatrice Michèle Garanger, Timothy Deming
  • Patent number: 10526397
    Abstract: The invention provides modifications within human or humanized single domain antibody fragments (sdAbs) that prevent recognition by pre-existing antibodies, to isolated polypeptides that include these modifications, and to methods and uses thereof.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: January 7, 2020
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Quinn Deveraux
  • Patent number: 10526398
    Abstract: The present invention relates to anti-virus dengue virus antibodies and applications thereof. Specifically, the anti-virus dengue virus antibodies of the present invention are serotype specific and useful for specific detection and differentiation of various dengue virus serotypes in a biological sample. The present invention also provide methods and kits for detecting dengue virus and methods and compositions for use in diagnosis and treatment of dengue virus disease using the anti-virus dengue virus antibodies as described herein.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: January 7, 2020
    Assignee: NATIONAL DEFENSE MEDICAL CENTER
    Inventors: Szu-Chia Lai, Yu-Yine Huang, Chang-Chi Lin, Jiunn-Jye Wey, Meng-Hung Tsai
  • Patent number: 10526399
    Abstract: Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: January 7, 2020
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Donald E. Ingber, Michael Super, Jeffrey Charles Way, Mark J. Cartwright, Julia B. Berthet, Dinah R. Super, Martin Rottman, Alexander L. Watters
  • Patent number: 10526400
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 7, 2020
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • Patent number: 10526401
    Abstract: Disclosed herein are split inteins, fused proteins of split inteins, and methods of using split inteins to efficiently purify and modify proteins of interest.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: January 7, 2020
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Tom W. Muir, Miquel Vila-Perello, Zhihua Liu, Neel H. Shah
  • Patent number: 10526402
    Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: January 7, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D'Andrea, Kalindi Parmar, Haojian Zhang
  • Patent number: 10526403
    Abstract: The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with Growth and Differentiation Factor 8 (GDF8) binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 7, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jesper Gromada, Esther Latres, Andrew J. Murphy, George D. Yancopoulos, Lori C. Morton
  • Patent number: 10526404
    Abstract: The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non-overlapping sites in a cytokine and an Fc moiety. The invention also relates to nucleic acids that encode such antibodies and antibody fragments and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of inflammatory and/or autoimmune diseases.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: January 7, 2020
    Assignee: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Davide Corti, Antonio Lanzavecchia, Luca Piccoli
  • Patent number: 10526405
    Abstract: An IL-31 dog pruritus model is provided. This model comprises administering canine IL-31 to dogs to produce a pruritic response; quantitatively measuring pruritic responses in the dogs which were administered canine IL-31; administering a candidate dog IL-31 inhibitor; and assessing the effectiveness of the candidate dog IL-31 inhibitor in reducing prurtic behavior in the treated dogs by challenging the dogs with canine IL-31 following the administration of the candidate dog IL-31 inhibitor.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: January 7, 2020
    Assignee: Zoetis Services LLC
    Inventors: Donald Wayne Mann, James Taylor Curry, Robert B. McCall, William R. Humphrey, Andrea Joy Gonzales, Gary Francis Bammert, Steven Alan Dunham
  • Patent number: 10526406
    Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR), under single-chain or multi-chain forms, the specificity of which, to a desired antigen, is conferred by a VNAR polypeptide derived from monomeric antibodies from cartilaginous fish. Such CARs, which aim to redirect immune cell specificity toward selected undesired malignant cells, are compact and thus particularly adapted to target hollow antigens such as ions channels of efflux pumps present at the surface of drug-resistant cells. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: January 7, 2020
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Julien Valton
  • Patent number: 10526407
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: January 7, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Leonie Alten, Dominik Maurer, Steffen Walter, Sebastian Bunk
  • Patent number: 10526408
    Abstract: In some aspects, mutant or variant Fc domains are provided that can exhibit increased affinity or selectivity for Fc?RIIB. The variant Fc domain may be a mutant IgG1 Fc domain. In some embodiments, a mutant or variant Fc domain may be present in a therapeutic antibody such as, e.g., an agonistic antibody. Additional methods for using and identifying mutant Fc domains are also provided.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: January 7, 2020
    Assignee: Research Development Foundation
    Inventors: George Georgiou, Chang-Han Lee
  • Patent number: 10526409
    Abstract: The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: January 7, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Birgitte Urso, Peter Andreas Nicolai Reumert Wagtmann, Inger Lund Pedersen, Anders Svensson
  • Patent number: 10526410
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 7, 2020
    Assignee: AnaptysBio, Inc.
    Inventors: Peter Bowers, Andrew John McKnight, David J. King, Marco Londei
  • Patent number: 10526411
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 7, 2020
    Assignee: Amgen Inc.
    Inventors: Chadwick Terence King, Gordon Ng, Shaw-Fen Sylvia Hu, Hung Nguyen, Jeannie Jung
  • Patent number: 10526412
    Abstract: An antibody or a fragment thereof directed against an epitope including or being constituted by at least six contiguous amino acids in the SEQ ID NO: 1 or a conformational epitope comprising or being constituted by at least six amino acids of SEQ ID NO: 1 which are always in the order of the sequence, and its use for the prognosis and/or the diagnosis of a cancer.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 7, 2020
    Assignees: UNIVERSITE GRENOBLE ALPES, UNIVERSITE DE LAUSANNE
    Inventors: Bertrand Huard, Pascal Schneider
  • Patent number: 10526413
    Abstract: The invention relates to antibody or antibody fragments thereof that bind to OX40, methods of producing these antibodies and fragments, and to methods of using the same.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: January 7, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Viktor Levitski, Pablo Umana
  • Patent number: 10526414
    Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: January 7, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Elizabeth E. Evans, Ernest S. Smith, Maurice Zauderer
  • Patent number: 10526415
    Abstract: The invention relates to human anti-Cath-D neutralizing monoclonal antibodies and uses thereof. More particularly, the invention relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: January 7, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Emmanuelle Liaudet-Coopman, Thierry Chardes, Pierre Martineau, Yahya Ashraf
  • Patent number: 10526416
    Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a KD value of 10 nM or lower, wherein the polypeptide inhibits neuregulin (NRG) binding to the human HER3 and NRG-induced cancer cell migration and proliferation. Additionally clones NG83 and NG140 are provided which bind human HER-3 with a KD value of 10 nM or lower.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: January 7, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yosef Yarden, Nadège Gaborit, Moshit Lindzen
  • Patent number: 10526417
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 7, 2020
    Assignee: XENCOR, INC.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • Patent number: 10526418
    Abstract: Compositions of modulators of acyl-CoA lysocardiolipin acyltransferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: January 7, 2020
    Assignee: The Penn State Research Foundation
    Inventor: Yuguang Shi
  • Patent number: 10526419
    Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: January 7, 2020
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Jie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
  • Patent number: 10526420
    Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: January 7, 2020
    Assignee: ABLEXIS, LLC
    Inventors: Larry Green, Hiroaki Shizuya
  • Patent number: 10526421
    Abstract: Esterified cellulose ethers which have i) as ester groups aliphatic monovalent acyl groups or groups of the formula —C(O)—R—COOA or a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, and ii) a content of not more than 0.85 weight percent acetone-insoluble esterified cellulose ether particles, when the esterified cellulose ether is present in a mixture of 12.5 weight parts of esterified cellulose ether and 87.5 weight parts of acetone at 21° C., the weight percent acetone-insoluble esterified cellulose ether particles being based on the total weight of the esterified cellulose ether, wherein iii) not more than 14 percent of the acetone-insoluble esterified cellulose ether particles have a particle size of more than 90 micrometers.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: January 7, 2020
    Inventors: Oliver Petermann, Matthias Knarr, Matthias Sprehe